Literature DB >> 17078260

Heart rate variability in rats with chronic hypoxic pulmonary hypertension.

L Fauchier1, A Melin, V Eder, D Antier, P Bonnet.   

Abstract

The precise role of pulmonary hypertension as a possible factor inducing a decrease in heart rate variability is poorly known. Spectral analysis of heart rate variability (HRV) was carried out in 21 Wistar rats before and after exposure to normoxia (N = 10) or to 3 weeks of hypobaric hypoxia inducing chronic pulmonary hypertension and right ventricular hypertrophy (N= 11). Continuous ECG was recorded in conscious animal at rest. Compared to the control group, rats exposed to hypoxia had a similar heart rate but a lower overall HRV (total power, 27.9 +/- 15.2 vs. 57.6 +/- 24.7 ms2, P < 0.01). Low frequency power (0.25-0.8 Hz) and high frequency power (0.8-3 Hz) were similar in both groups suggesting that HRV was decreased in the very low frequency power (0-0.25 Hz). The effects of atropine and propranolol on heart rate and HRV were similar in rats exposed or not to hypoxia. HRV is decreased in rats with hypoxic induced pulmonary hypertension, mainly in the very low frequency band, suggesting an increase in sympathetic activity. However, this decrease is moderate and the modulation of HRV with pharmacologic autonomic blockade remains similar to that of normal rats.

Entities:  

Mesh:

Year:  2006        PMID: 17078260     DOI: 10.1016/j.ancard.2006.01.005

Source DB:  PubMed          Journal:  Ann Cardiol Angeiol (Paris)        ISSN: 0003-3928


  2 in total

1.  Ventricular arrhythmic disturbances and autonomic modulation after beating-heart revascularization in patients with pulmonary normotension.

Authors:  Jus Ksela; Jurij Matija Kalisnik; Viktor Avbelj; Piotr Suwalski; Grzegorz Suwalski; Borut Gersak
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

2.  Diminazene aceturate improves autonomic modulation in pulmonary hypertension.

Authors:  Katya Rigatto; Karina R Casali; Vinayak Shenoy; Michael J Katovich; Mohan K Raizada
Journal:  Eur J Pharmacol       Date:  2013-05-09       Impact factor: 4.432

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.